^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Rituxan (rituximab)

    i
    Other names: R-105, RG-105, RO-45 2294, IDEC 102, RG105, IDEC-C2B8, RO-452294, R 105, RG 105, IDEC-102, R105, IDEC-C2B8 anti-CD20, RO 45-2294, Ro 45-2294, RO452294, RO 452294, IDEC102, IDEC C2BB
    Company:
    Biogen, Roche, Zenyaku Holdings
    Drug class:
    CD20 inhibitor
    Related drugs:
    19h
    The SREBF2-ACOT7 axis promotes tumor progression and predicts prognosis in diffuse large b-cell lymphoma. (PubMed, Sci Rep)
    Although the R-CHOP regimen effectively cures 60-70% of patients, 30-40% of patients relapse or develop resistance, highlighting the need for new biomarkers to improve prognosis and therapeutic strategies...Our findings suggest that the SREBF2-ACOT7 axis plays a critical role in DLBCL by promoting tumor cell growth, invasion, and survival. ACOT7 could serve as a potential prognostic biomarker and therapeutic target for DLBCL, providing new insights into the molecular mechanisms of this aggressive lymphoma.
    Journal
    |
    SREBF2 (Sterol Regulatory Element Binding Transcription Factor 2)
    |
    Rituxan (rituximab)
    1d
    Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial. (PubMed, Lancet Haematol)
    In patients with Richter transformation, epcoritamab monotherapy showed clinically meaningful antitumour activity, although the investigator-assessed overall response rate was below the alternative hypothesis of 50%, with a safety profile consistent with previous studies. These findings support further investigation of epcoritamab as a potential treatment option for patients with Richter transformation.
    P1/2 data • Journal
    |
    TP53 (Tumor protein P53)
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • Epkinly (epcoritamab-bysp)
    1d
    Extensive multifocal extranodal diffuse large B-cell lymphoma involving parotid, breast, gastrointestinal tract, and dorsal spine: a case report. (PubMed, Ann Med Surg (Lond))
    The patient was given R-CHOP chemotherapy and intrathecal methotrexate with a favorable early response...Image-guided biopsy and immunophenotyping at an early stage are crucial to avoid misdiagnosis and guide appropriate therapy. Individualized and risk-adapted approaches are crucial in maximizing the outcome in such aggressive and rare presentations.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    Rituxan (rituximab)
    2d
    AB-101-03: AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, Artiva Biotherapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • AlloNK (GCC4001)
    3d
    A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (clinicaltrials.gov)
    P2, N=60, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • imatinib • everolimus • Niktimvo (axatilimab-csfr)
    3d
    A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) (clinicaltrials.gov)
    P4, N=0, Withdrawn, Takeda | Trial completion date: Jul 2028 --> Aug 2025 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2028 --> Aug 2025
    Trial completion date • Trial withdrawal • Trial primary completion date
    |
    Rituxan (rituximab) • methotrexate IV
    3d
    Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease (clinicaltrials.gov)
    P2, N=25, Recruiting, Ruijin Hospital
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Inokai (orelabrutinib) • lisaftoclax (APG-2575)
    3d
    BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (PubMed, J Clin Oncol)
    Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.
    P3 data • Journal • IO biomarker
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IGH mutation
    |
    Rituxan (rituximab) • Jaypirca (pirtobrutinib) • bendamustine
    4d
    Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA) (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, University of Edinburgh
    New trial
    |
    Rituxan (rituximab)
    4d
    Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma (clinicaltrials.gov)
    P4, N=40, Recruiting, The First Affiliated Hospital of Soochow University
    New P4 trial
    |
    Rituxan (rituximab) • Jakafi (ruxolitinib) • Brukinsa (zanubrutinib)
    4d
    Go-Pro-DLBCL: Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Seoul National University Hospital
    New P1/2 trial
    |
    Rituxan (rituximab) • golcadomide (CC-99282) • poseltinib (HM71224)
    4d
    FIL_V-RBAC: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL (clinicaltrials.gov)
    P2, N=141, Completed, Fondazione Italiana Linfomi - ETS | Active, not recruiting --> Completed
    Trial completion
    |
    CCND1 (Cyclin D1) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • bendamustine